reports
Gilat to Highlight Next‑Generation Satellite Connectivity Technologies...
Gilat to Highlight Next‑Generation Satellite Connectivity Technologies at Satellite 2026 – “Expanding 5G to Space” Gilat accelerates the future of 5G NTN multi‑orbit, multi‑service connectivity for global mobility and broadband markets PETAH TIKVA, Israel, March 05, 2026 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, announced today that it will showcase a comprehensive suite of advanced next‑generation satellite communications solutions at Satellite 2026, taking place March 23...
Elinoil Sa: 2 directors
Two Directors at Elinoil Sa bought 273,820 shares at 1.830EUR. The significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Kraig Biocraft Laboratories Targets New Industrial and Defense Biomate...
Kraig Biocraft Laboratories Targets New Industrial and Defense Biomaterials as "Project Atlas" Hits Major Milestone ANN ARBOR, Mich., March 05, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced a major milestone in "Project Atlas", the Company's next-generation bioengineering initiative aimed at creating entirely new classes of materials for industrial and defense applications. Kraig Labs first disclosed the existence of Project Atlas on January 19th, 2026, when ...
Nephros Schedules Fourth Quarter 2025 Financial Results Conference Cal...
Nephros Schedules Fourth Quarter 2025 Financial Results Conference Call SOUTH ORANGE, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its fourth-quarter financial results on Thursday, March 12, 2026 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the ...
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results an...
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025 year-end cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Tr...
Om Freight Forwarders Ltd: 3 directors
Three Directors at Om Freight Forwarders Ltd bought/maiden bought 129,000 shares at between 79.995INR and 80.000INR. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the ...
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Eva...
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collabora...
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, ...
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer Former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women’s Hospital, Dr. Mina strengthens Invivyd’s medical leadership Dr. Mina’s research at Harvard focused on antibodies, vaccines, and infectious diseases with special expertise in COVID-19, measles, and other diseases, and will be a significant asset to Invivyd and the advancement of its pipelineWith mo...
AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease...
AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026 AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026 AC Immune to host symposium highlighting Precision Prevention approach to Parkinson's diseasePresentation at International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD™ 2026) showcases potential of first-in-class TDP-43 PET-tracer ACI-19626 Lausanne, Switzerland, March 5, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision th...
Herantis Pharma releases 2H and FY 2025 report today
Herantis Pharma releases 2H and FY 2025 report today Herantis Pharma Plc | Company Release | March 5, 2026 at 08:00:00 EET Espoo, Finland, March 5, 2026: Herantis Pharma Plc ("Herantis") a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, releases today the Company’s 2H and FY 2025 report. The full report is attached to this release and is also available on the Company’s website: . Commenting on the results, Antti Vuolanto, CEO of Herantis Pharma, said: “2025 was a year of significant progress for Herantis Pharma, highlighted by ...
GlobalFoundries Announces 2026 Investor Day
GlobalFoundries Announces 2026 Investor Day MALTA, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- GlobalFoundries (NASDAQ: GFS) today announced that it will host its Investor Day on Thursday, May 7, 2026, beginning at 9:00 a.m. ET in New York City. GlobalFoundries’ Investor Day will feature presentations from its leadership team regarding the company’s strategy, growth initiatives, and long-term outlook, followed by a Q&A session. A live video webcast and replay will be made available on GlobalFoundries’ Investor Relations website at . Further details and webcast registration is available . A...
Lantronix Avança na Estratégia de Escalonamento de Plataforma com a Ex...
Lantronix Avança na Estratégia de Escalonamento de Plataforma com a Expansão da Computação Embarcada Baseada em MediaTek Expansão estratégica fortalece a estratégia de plataforma multissilício, amplia o mercado endereçável e acelera o crescimento em Industrial IoT e Edge AI IRVINE, Califórnia, March 05, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: LTRX), líder global em soluções de IoT de computação e conectividade que alimentam aplicativos Edge AI, anunciou hoje uma expansão estratégica significativa da sua plataforma de computação embarcada com as novas soluções System-on-Module (SOM) baseadas n...
Lantronix เดินหน้าพัฒนาแผนกลยุทธ์การขยายแพลตฟอร์มด้วยการขยายการประมวลผ...
Lantronix เดินหน้าพัฒนาแผนกลยุทธ์การขยายแพลตฟอร์มด้วยการขยายการประมวลผลแบบฝังโดยใช้ MediaTek การขยายเชิงกลยุทธ์ช่วยเสริมความแข็งแกร่งให้กับกลยุทธ์แพลตฟอร์มหลายซิลิคอน ขยายตลาดเป้าหมาย และเร่งการเติบโตทั่วทั้ง Industrial IoT และ Edge AI เออร์ไวน์ แคลิฟอร์เนีย, March 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LTRX) ผู้นำระดับโลกด้านโซลูชันการประมวลผลและ IoT การเชื่อมต่อ ที่ขับเคลื่อนแอปพลิเคชัน Edge AI ประกาศในวันนี้ถึงการขยายเชิงกลยุทธ์ครั้งสำคัญของแพลตฟอร์มการประมวลผลแบบฝังผ่านโซลูชัน System-on-Module (SOM) ใหม่ที่ใช้แพลตฟอร์ม System-on-Chip (SOC) ตระกูล Genio จาก (TWSE: 2454) ผู้นำระดับโล...
Lantronix 借助基于 MediaTek 的嵌入式计算扩展，推进平台规模化战略
Lantronix 借助基于 MediaTek 的嵌入式计算扩展，推进平台规模化战略 此次战略扩张强化多硅平台战略，拓宽可覆盖市场，加速工业物联网与边缘 AI 领域的增长 加利福尼亚州尔湾, March 05, 2026 (GLOBE NEWSWIRE) -- 边缘 AI 应用计算与物联网连接解决方案的全球领导者 (Nasdaq: LTRX) 今日宣布，将通过基于 (TWSE: 2454) Genio 系列系统级芯片 (SOC) 平台的新型系统级模块 (SOM) 解决方案，对其嵌入式计算平台实施重大战略扩张。后者作为全球领先的无晶圆厂半导体设计企业，每年为全球超过 20 亿台联网设备提供支持。 此次扩张标志着 Lantronix 在嵌入式计算生态系统规模化方面迈出了战略性一步，不仅拓宽了解决方案组合、扩大了市场覆盖范围，还增强了其服务高增长工业和商业边缘 AI 部署的能力。 通过扩展其硅基架构，Lantronix 进一步提升了在更广泛部署需求和容量层级中，提供性能优化且能效卓越的计算平台的能力。 Lantronix 首席战略官 Mathi Gurusamy 表示：“MediaTek 拓展了我们在边缘 AI 特定部署领域的服务能力——这些部署专为优化功耗、性能与成本比，以及实现可扩展量产而设计。 通过满足这些差异化工作负载需求，我们不仅扩大了总可寻址市场规模、增强...
Lantronix 運用以 MediaTek 為基礎的嵌入式運算擴充解決方案，推動平台擴展策略
Lantronix 運用以 MediaTek 為基礎的嵌入式運算擴充解決方案，推動平台擴展策略 此策略性擴展不僅強化多晶片平台策略，還擴大潛在市場，並加快工業物聯網及邊緣人工智能的業務增長 加州爾灣, March 05, 2026 (GLOBE NEWSWIRE) -- 為邊緣人工智能 (Edge AI) 應用提供動力的運算和連接物聯網 (IoT) 解決方案全球領導者 (Nasdaq: LTRX) 今日宣佈其嵌入式運算平台迎來重大策略擴展，將推出以 (TWSE: 2454) 為基礎，Genio 系列系統晶片 (SOC) 平台的全新系統模組 (SOM) 解決方案。MediaTek Inc. 是無晶圓半導體設計的全球龍頭企業，每年驅動全球超過 20 億部聯網裝置。 是次擴展是 Lantronix 擴大嵌入式運算生態系統的策略舉措，目的在於擴闊解決方案組合、增加市場覆蓋範圍，並加強服務高速增長的工商業邊緣人工智能 (Edge AI) 部署。 透過擴充晶片基礎，Lantronix 能在更多元的部署要求和出貨量級別上，提供性能卓越且高能源效益的運算平台。 Lantronix 策略總監 Mathi Gurusamy 表示：「MediaTek 讓我們能更有效地服務 Edge AI 部署中的特定領域，這些項目特別看重能源效益、性價比以及可擴展的量產能力。 回應這些不同的工作量...
Verisk Reiterates its Growth Targets and Outlines Strategy for its Nex...
Verisk Reiterates its Growth Targets and Outlines Strategy for its Next Phase of Compounding Growth at 2026 Investor Day JERSEY CITY, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Verisk (Nasdaq: VRSK), a leading strategic data analytics and technology partner to the global insurance industry, will host its Investor Day today at 8 a.m. ET, where Verisk President and CEO Lee Shavel, CFO Elizabeth Mann and members of the company’s senior leadership team will outline the company’s strategy, competitive positioning and financial framework designed to deliver durable, compounding growth and strong ...
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from C...
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal BXCL501 demonstrated clinical benefits and favorable tolerability profile for treatment of opioid withdrawal symptoms Results from this NIDA-funded study support potential future development of BXCL501 in opioid withdrawal Opioid use disorder is a global health crisis, affecting approximately 5.9 million adults in the U.S. NEW HAVEN, Conn., March 05, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company ...
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Result...
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates Initiation of Phase 3 MASH trial planned for 2026 Pemvidutide granted FDA Breakthrough Therapy Designation in MASH Topline data from RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder (AUD) expected in third quarter 2026 Cash, cash equivalents and short-term investments of $274 million as of December 31, 2025; Balance sheet further strengthened through $75 million registered direct offering in January 2026 Webcast to be held today, March 5, 2026, at 8:30 a.m. ET GAITHERSBURG, Md., Ma...
Plug Power to Ring the Nasdaq Stock Market Closing Bell on March 6, 20...
Plug Power to Ring the Nasdaq Stock Market Closing Bell on March 6, 2026 Company celebrates Plug’s strong full year 2025 results and newly appointed CEO, Jose Luis Crespo SLINGERLANDS, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, will visit the NASDAQ MarketSite in Times Square to ring the Closing Bell on Friday, March 6, 2026. The Closing Bell ceremony celebrates as well as its newly appointed CEO, Jose Luis Crespo, who officially took the helm of the company on March 2, 2026. Full-year 2025 re...
Skye Bioscience to Announce 2025 Financial Results and Business Update...
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026 SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Tuesday, March 10th at 1:30 p.m. PT/4:30 p.m. ET to discuss its 2025 fourth quarter and full-year financial results and business update. An earnings press release will be issued after the market closes on March 10th. The live webcast of the call ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.